Pharmas are increasingly outsourcing R&D to CROs to expedite drug development and reduce costs. The model is working well so far, as the fast production of the Covid-19 vaccine showed. CROs perform their tasks efficiently and are growing in number, size and scope. There are, however, important risks in this strategy which should be considered. Understanding this unique model is enriching not only for the pharma industry but also for those interested in the generation of new knowledge and in outsourcing. Sigue leyendo
Follow me in Twitter
Twitter: @BlancaSanchezR1Blog Ideas 4.0
Categorías
- Actualidad
- Argentina
- Brazil
- Brexit
- cine
- cinema
- Contract Research Organization
- COVID-19
- cultura
- DEA
- Desarrollo de carrera
- economía
- economía mundial
- Economics
- Efficiency
- Empresa
- Estrategia empresarial
- European Union
- Investigación
- Latin America
- Mercado laboral
- Mexico
- Outsourcing
- pharmaceutical industry
- piscología
- Política
- política monetaria
- R&D
- Recursos para estudiantes
- series
- Tariffs
- tipos de interés
- UK
- Uncategorized
- Universidad
- World trade